Trending...
- California: Governor Newsom announces nearly $1.3 billion for cleaner transportation, stronger transit connections - 119
- California: Governor Newsom issues emergency proclamations to support recovery in Humboldt and Imperial counties - 118
- At COP31, Governor Newsom announces $81 million to fund climate-smart agriculture projects to support California farmers across 55 counties - 117
OXFORD, England and CHICAGO, May 16, 2025 ~ Brainomix, a leading company in AI-powered imaging solutions for lung fibrosis and stroke, will be presenting new evidence at the upcoming American Thoracic Society (ATS) Conference in San Francisco. The evidence will validate the effectiveness of their Brainomix 360 e-Lung technology in accurately and sensitively identifying progressive pulmonary fibrosis.
The validation comes as a result of a research collaboration between Brainomix and Boehringer Ingelheim, a global leader in pulmonary fibrosis therapies. Through this collaboration, Brainomix was granted access to the landmark INBUILD clinical trial dataset to conduct the first quantitative CT analysis. The results have firmly established e-Lung as a reliable tool for identifying progressive pulmonary fibrosis and its prognostic accuracy in predicting patients at risk.
Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim, expressed their commitment to creating value for patients through collaborations. She stated that the imaging data presented at ATS from their INBUILD clinical trial is part of their collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy.
More on The Californer
The studies will be presented on May 21st at ATS by Prof Anand Devaraj and Dr Peter George from the Royal Brompton Hospital in London. They will showcase Brainomix 360 e-Lung, an imaging software powered by novel proprietary technology that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD). With its recent expansion of FDA clearance, the next generation e-Lung technology represents a significant step forward in improving care for ILD patients with improved AI and machine learning algorithms.
Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Without treatment, patients can have a lifespan as short as three to five years from diagnosis. However, due to challenges in identifying the disease, patients often wait up to two years for a diagnosis. Early initiation of treatment is crucial for the best outcome and survival, but identifying eligible patients based on imaging can be difficult, even for experts.
Dr Peter George, Consultant Pulmonologist at the Royal Brompton NHS Trust UK and Brainomix Medical Director, emphasized the power of e-Lung in accurately identifying progression and its prognostic capabilities. He stated that this ability to track results across multiple scan timepoints can help physicians make better treatment decisions earlier on. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up and escalate their care in a timely manner.
More on The Californer
The strategic partnership between Brainomix and Boehringer Ingelheim, announced in 2024, aims to improve the care of patients with progressive pulmonary fibrosis. Early collaborations with leading US pulmonary sites and registries have already provided real-world validation of e-Lung in improving the identification of patients with progressive pulmonary fibrosis.
Brainomix will be exhibiting at ATS (booth #1563) and will have a series of key scientific sessions. The "Imaging-Based Advances in Fibrotic ILD" symposium will take place on Wednesday, May 21 from 11am – 1pm in Rooms 3014-3018, West Building of the Moscone Center. Three (3) Brainomix studies will be presented by Dr Peter George and Prof Anand Devaraj:
- e-Lung Biomarkers Are Associated With Future Progressive Pulmonary Fibrosis Independent of UIP Status on CT
- Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
- Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
In conclusion, Brainomix's innovative e-Lung technology, validated by their collaboration with Boehringer Ingelheim, has the potential to significantly improve the care and outcomes of patients with progressive pulmonary fibrosis. Their studies and presentations at ATS will provide valuable insights and advancements in the field of ILD imaging.
The validation comes as a result of a research collaboration between Brainomix and Boehringer Ingelheim, a global leader in pulmonary fibrosis therapies. Through this collaboration, Brainomix was granted access to the landmark INBUILD clinical trial dataset to conduct the first quantitative CT analysis. The results have firmly established e-Lung as a reliable tool for identifying progressive pulmonary fibrosis and its prognostic accuracy in predicting patients at risk.
Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim, expressed their commitment to creating value for patients through collaborations. She stated that the imaging data presented at ATS from their INBUILD clinical trial is part of their collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy.
More on The Californer
- City of Long Beach Facilities and Services Thanksgiving Week Schedule
- Nook Vans Takes Healthcare on the Road with GE Technology
- 1 FUR 1 and First Responder Therapy Dogs Unite to Strengthen First Responder Wellness Thro
- Wade Mortenson Photography Publishes Free Guide to Family Photos at Oceanside Pier
- A 35-Year-Old 16-Bit Holy Grail: The Elusive Twinkle Tale Finally Arrives in North America & Europe
The studies will be presented on May 21st at ATS by Prof Anand Devaraj and Dr Peter George from the Royal Brompton Hospital in London. They will showcase Brainomix 360 e-Lung, an imaging software powered by novel proprietary technology that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD). With its recent expansion of FDA clearance, the next generation e-Lung technology represents a significant step forward in improving care for ILD patients with improved AI and machine learning algorithms.
Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Without treatment, patients can have a lifespan as short as three to five years from diagnosis. However, due to challenges in identifying the disease, patients often wait up to two years for a diagnosis. Early initiation of treatment is crucial for the best outcome and survival, but identifying eligible patients based on imaging can be difficult, even for experts.
Dr Peter George, Consultant Pulmonologist at the Royal Brompton NHS Trust UK and Brainomix Medical Director, emphasized the power of e-Lung in accurately identifying progression and its prognostic capabilities. He stated that this ability to track results across multiple scan timepoints can help physicians make better treatment decisions earlier on. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up and escalate their care in a timely manner.
More on The Californer
- GIVING TUESDAY: Help Indigenous Families in Guatemala Build Healthy, Self-Reliant Futures
- Get Care at Home Joins Inaugural Zest Fest Business Expo in Citrus Heights
- Prices Are Coming Down: Ten High Desert Properties Show Big Price Cuts
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
- Judd Saves ChatGPT Shoppers Money on Holiday Gifts
The strategic partnership between Brainomix and Boehringer Ingelheim, announced in 2024, aims to improve the care of patients with progressive pulmonary fibrosis. Early collaborations with leading US pulmonary sites and registries have already provided real-world validation of e-Lung in improving the identification of patients with progressive pulmonary fibrosis.
Brainomix will be exhibiting at ATS (booth #1563) and will have a series of key scientific sessions. The "Imaging-Based Advances in Fibrotic ILD" symposium will take place on Wednesday, May 21 from 11am – 1pm in Rooms 3014-3018, West Building of the Moscone Center. Three (3) Brainomix studies will be presented by Dr Peter George and Prof Anand Devaraj:
- e-Lung Biomarkers Are Associated With Future Progressive Pulmonary Fibrosis Independent of UIP Status on CT
- Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
- Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results From the INBUILD Trial
In conclusion, Brainomix's innovative e-Lung technology, validated by their collaboration with Boehringer Ingelheim, has the potential to significantly improve the care and outcomes of patients with progressive pulmonary fibrosis. Their studies and presentations at ATS will provide valuable insights and advancements in the field of ILD imaging.
Filed Under: Business
0 Comments
Latest on The Californer
- Markets for Makers Port of LA Holiday Market
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- Long Beach: Construction to Begin at El Dorado Nature Center for New Parking Improvement System
- At COP31, Governor Newsom announces $81 million to fund climate-smart agriculture projects to support California farmers across 55 counties
- Pervaziv AI Advances Cortex Code 2.0 for Deeper Reasoning Across Complex Codebases
- Berberine, Daruharidra in Ayurvedic Medicine, Dr. Abhay Kumar Pati, Physician, Researcher,
- Attn: Media Companies & Publishing Companies: Want to Increase your Advertising Revenues very substantially? Check out all these Projects & Promotions
- City of Long Beach Issues Rain Advisory Due to Recent Showers
- FM2 & Intentional: "I Survived" — A Powerful Anthem of Faith, Perseverance and Purpose
- 98.FM Gospel Radio Realigns Airwaves: Prioritizing Scripture and New Artists Over Secular Metrics
- Free DUI Help Center Gives California Drivers Answers Without the Referral Fees
- This Holiday Season, More Orange County Residents Are Fixing Their Phones Instead of Replacing Them
- Clustir Launches Teams to Simplify Sports Management
- Diamond in the Raw Foundation Unites Hollywood Leaders for Diamonds & Decision Makers Mixer
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Get Care at Home Sponsors Citrus Heights HART's 2026 Spaghetti Fest
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Elevate Your Everyday Style with Designer Earrings and Luxury Designs